Roche To Take Ionis Drug Forward Into Crowded Nephropathy Field

Also Has Potential In AMD

Roche is not disclosing Phase II results yet, but must exceed late-stage rival drug’s 50% reduction in protein build up to compete in immunoglobulin A nephropathy.

Ionis HQ — Roche will lead the Phase III development of the therapy, based on Ionis' antisense drug platform. • Source: Ionis

Roche is to license Ionis Pharmaceuticals’ antisense candidate IONIS-FB-LRx and take it into a Phase III study in patients with immunoglobulin A nephropathy (IgAN), an additional potential indication.

The two firms already have a collaboration for the product in eye diseases and will now add this rare and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

06 Jun 2025

• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

04 Jun 2025

• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

04 Jun 2025

• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.